Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass.

Audrick GibertJulien LanoiseléeIsabelle Gouin-ThibaultAdeline PontisKasra AzarnoushAndranik PetrosyanNathalie GrandSerge MolliexJérome MorelLaurent GergeléSophie HodinValérie BinRobin ChauxXavier DelavenneEdouard Ollier

Published in: Clinical pharmacokinetics (2024)

The population model effectively characterized UFH's pharmacokinetics/pharmacodynamics in cardiopulmonary bypass patients. This meta-analysis incorporated new covariates related to UFH's pharmacokinetics/pharmacodynamics, enabling personalized dosing regimens. The proposed model holds potential for individualization using a Bayesian estimation.

Keyphrases

systematic review
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
venous thromboembolism
randomized controlled trial
risk assessment
growth factor
human health
drug induced